# **HOW I SEE THE FUTURE OF CAS** FRANKJ. VEITH MEET - 2015NICE – JUNE 9, 2015

# THE SHORT ANSWER IS THE FUTURE IS BRIGHT

**DESPITE CURRENT LEVEL 1 EVIDENCE** THE OUTLOOK FOR AN UPSURGE IN **CAROTID STENTING (CAS) IS BRIGHT & THEREFORE WEARE READY FOR** THE NEXT BREAKTHROUGH


I HAVE NO FINANCIAL CONFLICTS ALTHOUGH I HAVE LOTS OF BIASES

**DESPITE SOME OPINIONS TO THE CONTRARY CAROTID STENTING OR CAS IS CURRENTLY IN DECLINE** GENERALLY FOR TREATMENT OF SYMP & **ASYMPTOMATIC CAR STENOSIS** THIS IS BECAUSE...

WITH SYMPTOMATIC **CAROTID STENOSIS** PATIENTS **RECENT RCTs\* & POPUL STUDIES SHOW HIGHER STROKE RATES** WITH CAS THAN CEA, AND... \*(CREST, ICSS, ETC)

WITH MOST ASYMPTOMATIC CAROTID STENOSIS PATIENTS


BEST MEDICAL TREATMENT HAS SUCH LOW STROKE RATES THAT IT MAKES MOST CAS (& CEA) UNNECESSARY





ANNUAL STROKE RATE WITH ASX CS DECREASED DUE TO BETTER BMRx & STATINS FROM 3-6% TO <1% / YR FROM A ABBOTT & R NAYLOR HOWEVER, I BELIEVE OUTLOOK FOR CAS IS BRIGHT BECAUSE 3 ADVANCES MAY DECR STROKES, IMPROVE CAS RESULTS & MAKE CURR RCTs OBSOLETE


- 1. BETTER EMBOL PROTECT DEVICES WITH CESS/REVERSAL OF FLOW
- 2. CERVICAL ACCESS (SILK ROAD SYSTEM) TO AVOID THE AORTIC ARCH & REV FL
- 3. MEMBRANE OR MESH COVERED STENTS TO STOP DELAYED STROKES

# **OUR 1995 EX VIVO MODEL OF CAS**











HOWEVER, I BELIEVE OUTLOOK FOR CAS IS BRIGHT BECAUSE 3 ADVANCES MAY DECR STROKES, IMPROVE CAS RESULTS & MAKE CURR RCTs OBSOLETE

- 1. BETTER EMBOL PROTECT DEVICES WITH CESS/REVERSAL OF FLOW
- 2. CERVICAL ACCESS (SILK ROAD SYSTEM) TO AVOID THE AORTIC ARCH & REV FL
- 3. MEMBRANE OR MESH COVERED STENTS TO STOP DELAYED STROKES



### DEBRIS THOUGH STENT CAUSING DELAYED EMBOLI



### A MESH COVERED STENT TO PREVENT DELAYED EMBOLIZATION


### Dual layer micromesh design for sustained embolic protection.




### **ROADSAVER FROM TERUMO**

### THE THREE MICROMESH CAROTID STENTS








From Max Amor

### CGuard<sup>TM</sup> carotid embolic protection technology with MicroNet<sup>TM</sup> by InspireMD





HOWEVER, I BELIEVE OUTLOOK FOR CAS IS BRIGHT BECAUSE 3 ADVANCES MAY DECR STROKES, IMPROVE CAS RESULTS & MAKE CURR RCTs OBSOLETE


- 1. BETTER EMBOL PROTECT DEVICES WITH CESS/REVERSAL OF FLOW
- 2. CERVICAL ACCESS (SILK ROAD SYSTEM) TO AVOID THE AORTIC ARCH & REV FL
- 3. MEMBRANE OR MESH COVERED STENTS TO STOP DELAYED STROKES

SILK ROAD CERVICAL ACCESS SYSTEM WITH REVERSAL OF FLOW

Following Slides Courtesy Of Chris Kwolak & Sumaira Macdonald

### A NEW, SURGICALLY-INSPIRED ENDOVASCULAR SOLUTION

### **ENROUTE™ Transcarotid Stent and Neuroprotection System**



CAUTION: Investigational device. Limited by federal (USA) law to investigational use. The ENROUTE™ Transcarotid Stent and Neuroprotection Systems bear the CE mark of conformity and are available for sale in EU and EFTA countries.



### **SURGICAL OUTCOMES IN STROKE REDUCTION**

	Silk Road Clinical Studies		
	PROOF	TESLA	ROADSTER
Study type	First In Man	Multicenter EU Post- Market Registry	US Pivotal IDE
Number of Patients	75	58	141
Profile	All-comers	All-comers	High Surgical Risk
Status	Complete	Complete	Enrollment Complete



## FOR SYMPTOMATIC & ASX PTS IF THESE 3 ADVANCES DECREASE CAS STROKE RATES

CAS WOULD BE MORE COMPETITIVE TO CEA & WOULD REPLACE CEA MORE WIDELY THAN IT DOES NOW

FOR ASYMPTOMATIC PATIENTS THERE ARE PROMISING WAYS **ON THE HORIZON TO SELECT** THOSE AT HIGH RISK OF STROKE **1. TCD DETECTED MICROEMBOLI** 2. DUPLEX PLAQUE EVALUATION 3. MRI & CT PLAQUE EVALUATION 4. SILENT MRI & CT INFARCTS SOME ASX PT GROUPS HAVE >12% PER YEAR STROKE RISK vs <1%

THESE HIGH RISK **ASYMPTOMATIC PTS SELECTED BY THESE METHODS CLEARLY WOULD BENEFIT FROM CAS OR CEA - IN ADDITION TO BEST MEDICAL TREATMENT** THUS INCREASING THE NUMBER **OF PATIENT NEEDING CAS** 

### **HOWEVER THERE IS 1 RESERVATION:**

THAT IS THE EFFICACY OF THESE 3 METHODS FOR DECREASING CAS STROKE RATES & IMPROVING ASX PATIENT SELECTION MUST BE PROVEN BY APPROPRIATE CLINICAL TRIALS

# **MY CONCLUSIONS**

**1. DESPITE THIS RESERVATION I BELIEVE THE OUTLOOK FOR CAROTID STENTING OR CAS IS BRIGHT IN THE FUTURE** 2. ALL VASCULAR SPECIALISTS SHOULD PREPARE FOR **IMPROVING CAS RESULTS** 

### THANKS FOR YOUR ATTENTION



### THE SILK ROAD PROCEDURE

- Surgically Inspired *It's All about stroke*
  - Direct carotid access with CCA clamp & vessel control
  - Robust flow reversal akin to backbleeding
  - No discrimination macro and micro emboli
- Transcarotid Endovascular Advantage
  - Procedural speed and interventional device control
  - Shorter delivery system and wires for simplified setup and delivery
  - Broad population of patients eligible for this procedure
- Patient Friendly, Less Invasive Procedure
  - Reduced rate and severity of cranial nerve injury
  - Local anesthesia can improve recovery time
  - Cosmetic result of a less invasive procedure

ROADSTER Study to be presented at VIVA and VEITH, 2014

